Unnamed: 0,title,date,stock,sentiment
393056.0,10 Biggest Price Target Changes For Tuesday,2020-06-09 08:15:00-04:00,DXCM,neutral
393057.0,"Raymond James Maintains Outperform on DexCom, Raises Price Target to $395",2020-06-09 07:15:00-04:00,DXCM,neutral
393058.0,"DexCom shares are trading lower, not currently seeing company-specific news for the session. NOTE: Stock has gained on heavy momentum this year and appears to be giving back some gains following run up.",2020-06-04 13:27:00-04:00,DXCM,positive
393059.0,"Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.",2020-05-28 12:33:00-04:00,DXCM,positive
393060.0,"Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $450",2020-05-27 08:16:00-04:00,DXCM,negative
393061.0,Trump Says Reached 'Breakthrough' Agreement On Cost Of Insulin,2020-05-26 16:34:00-04:00,DXCM,positive
393062.0,"The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering",2020-05-19 08:24:00-04:00,DXCM,positive
393063.0,Stocks That Hit 52-Week Highs On Monday,2020-05-18 10:44:00-04:00,DXCM,neutral
393064.0,"Benzinga's Top Upgrades, Downgrades For May 14, 2020",2020-05-14 09:31:00-04:00,DXCM,positive
393065.0,"Wells Fargo Initiates Coverage On DexCom with Equal-Weight Rating, Announces Price Target of $420",2020-05-14 07:27:00-04:00,DXCM,positive
393066.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,DXCM,negative
393067.0,'Jim Cramer reviews top 10 stocks 'for this difficult moment' on the 'Cramer Covid-19 Index'' -CNBC,2020-05-11 21:48:00-04:00,DXCM,negative
393068.0,Stocks That Hit 52-Week Highs On Monday,2020-05-11 10:28:00-04:00,DXCM,neutral
393069.0,DexCom Announces Proposed Offering of $850M of Convertible Senior Notes,2020-05-11 07:40:00-04:00,DXCM,neutral
393070.0,"The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda",2020-05-08 07:59:00-04:00,DXCM,neutral
393071.0,Stocks That Hit 52-Week Highs On Thursday,2020-05-07 10:33:00-04:00,DXCM,neutral
393072.0,DexCom shares are trading higher after S&P Dow Jones Indices announced DexCom is set to join the S&P 500.,2020-05-07 08:41:00-04:00,DXCM,positive
393073.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,DXCM,negative
393074.0,S&P Dow Jones Indices Announces 'DexCom & Domino's Pizza Set to Join S&P 500; Salesforce.com to Join S&P 100; STORE Capital to Join S&P MidCap 400; Capri Holdings to Join S&P SmallCap 600',2020-05-06 17:18:00-04:00,DXCM,positive
393075.0,Stocks That Hit 52-Week Highs On Wednesday,2020-05-06 10:43:00-04:00,DXCM,neutral
393076.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,DXCM,positive
393077.0,"Cramer Gives His Opinion On Tandem Diabetes, JPMorgan And More",2020-05-06 07:15:00-04:00,DXCM,neutral
393078.0,Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session.,2020-05-05 12:44:00-04:00,DXCM,positive
393079.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-05 10:48:00-04:00,DXCM,neutral
393080.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,DXCM,positive
393081.0,Watching Dexcom Shares As Hearing David Einhorn Q1 Letter To Greenlight Investors Shows Covered Short In Stock,2020-05-01 09:44:00-04:00,DXCM,positive
393082.0,"The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO",2020-05-01 07:54:00-04:00,DXCM,neutral
393083.0,Stocks That Hit 52-Week Highs On Thursday,2020-04-30 10:31:00-04:00,DXCM,neutral
393084.0,"UBS Maintains Neutral on DexCom, Raises Price Target to $335",2020-04-30 09:31:00-04:00,DXCM,neutral
393085.0,"The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1",2020-04-30 07:19:00-04:00,DXCM,positive
393086.0,108 Biggest Movers From Yesterday,2020-04-30 05:30:00-04:00,DXCM,neutral
393087.0,"Guggenheim Maintains Buy on DexCom, Raises Price Target to $395",2020-04-29 13:35:00-04:00,DXCM,neutral
393088.0,82 Stocks Moving In Wednesday's Mid-Day Session,2020-04-29 12:50:00-04:00,DXCM,neutral
393089.0,"Citigroup Maintains Buy on DexCom, Raises Price Target to $361",2020-04-29 11:36:00-04:00,DXCM,neutral
393090.0,"Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $375",2020-04-29 10:06:00-04:00,DXCM,negative
393091.0,"Stifel Maintains Buy on DexCom, Raises Price Target to $385",2020-04-29 09:40:00-04:00,DXCM,neutral
393092.0,"JP Morgan Maintains Overweight on DexCom, Raises Price Target to $360",2020-04-29 09:36:00-04:00,DXCM,neutral
393093.0,"Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $377",2020-04-29 08:46:00-04:00,DXCM,neutral
393094.0,"The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda",2020-04-29 08:40:00-04:00,DXCM,positive
393095.0,"Oppenheimer Maintains Outperform on DexCom, Raises Price Target to $360",2020-04-29 08:31:00-04:00,DXCM,neutral
393096.0,"Raymond James Maintains Outperform on DexCom, Raises Price Target to $360",2020-04-29 08:30:00-04:00,DXCM,neutral
393097.0,DexCom shares are trading higher after the company reported better-than-expected Q1 sales results.,2020-04-29 07:50:00-04:00,DXCM,positive
393098.0,35 Stocks Moving in Wednesday's Pre-Market Session,2020-04-29 07:21:00-04:00,DXCM,neutral
393099.0,23 Stocks Moving In Tuesday's After-Hours Session,2020-04-28 17:20:00-04:00,DXCM,neutral
393100.0,DexCom shares are trading higher after the company reported better-than-expected Q1 sales results.,2020-04-28 16:10:00-04:00,DXCM,positive
393101.0,"DexCom Q1 EPS $0.440 May Not Compare To $0.140 Estimate, Sales $405.100M Beat $358.620M Estimate",2020-04-28 16:03:00-04:00,DXCM,neutral
393102.0,"The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update",2020-04-28 07:36:00-04:00,DXCM,neutral
393103.0,"Raymond James Maintains Outperform on DexCom, Raises Price Target to $350",2020-04-27 11:38:00-04:00,DXCM,neutral
393104.0,Stocks That Hit 52-Week Highs On Monday,2020-04-27 10:21:00-04:00,DXCM,neutral
393105.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,DXCM,negative
393106.0,Shares of several healthcare companies are trading higher as equities gain amid oil prices potentially stabilizing following the recent crash.,2020-04-22 12:03:00-04:00,DXCM,positive
393107.0,Stocks That Hit 52-Week Highs On Friday,2020-04-17 10:19:00-04:00,DXCM,neutral
393108.0,"The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement",2020-04-17 07:35:00-04:00,DXCM,positive
393109.0,Stocks That Hit 52-Week Highs On Thursday,2020-04-16 10:19:00-04:00,DXCM,neutral
393110.0,Shares of several healthcare companies are trading higher amid overall market strength after the US Federal Reserve announced a further $2.3 trillion in financing programs to support the economy. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic and US Senator Sanders exiting the Presidential race.,2020-04-09 09:58:00-04:00,DXCM,positive
393111.0,Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign.,2020-04-08 09:34:00-04:00,DXCM,positive
393112.0,Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.,2020-04-01 09:20:00-04:00,DXCM,negative
393113.0,DexCom shares are trading higher despite market weakness. Morgan Stanley analysts today maintained an Equal-Weight rating on the stock and raised the price target from $270 to $278.,2020-03-27 11:55:00-04:00,DXCM,positive
393114.0,"Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $278",2020-03-27 09:27:00-04:00,DXCM,neutral
393115.0,"Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors.",2020-03-26 11:49:00-04:00,DXCM,positive
393116.0,"Stephens & Co. Maintains Overweight on DexCom, Lowers Price Target to $240",2020-03-23 11:26:00-04:00,DXCM,negative
393117.0,DexCom shares are trading higher despite overall market weakness. Not currently seeing company-specific news.,2020-03-18 11:10:00-04:00,DXCM,positive
393118.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 09:40:00-04:00,DXCM,negative
393119.0,DexCom shares are trading lower despite market strength. Not currently seeing negative company-specific news.,2020-03-13 11:21:00-04:00,DXCM,positive
393120.0,"Oppenheimer Maintains Outperform on DexCom, Raises Price Target to $305",2020-03-06 11:39:00-05:00,DXCM,neutral
393121.0,Lipper Award Winners Pick Healthcare and Technology Stocks Amidst Coronavirus Downturn,2020-03-06 08:33:00-05:00,DXCM,positive
393122.0,"Benzinga's Top Upgrades, Downgrades For March 5, 2020",2020-03-05 10:05:00-05:00,DXCM,positive
393123.0,"Citigroup Initiates Coverage On DexCom with Buy Rating, Announces $330 Price Target",2020-03-05 05:16:00-05:00,DXCM,neutral
393124.0,Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.,2020-02-24 08:37:00-05:00,DXCM,negative
393125.0,"The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion",2020-02-21 07:46:00-05:00,DXCM,negative
393126.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,DXCM,negative
393127.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-19 10:32:00-05:00,DXCM,neutral
393128.0,"The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA",2020-02-19 07:21:00-05:00,DXCM,negative
393129.0,Dexcom And Insulet Announce Commercial Agreement To Integrate The Dexcom G6 And Future G7 CGM Into Insulet's Omnipod Horizon Automated Insulin Delivery System,2020-02-19 07:10:00-05:00,DXCM,positive
393130.0,"Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $270",2020-02-18 07:47:00-05:00,DXCM,neutral
393131.0,76 Biggest Movers From Friday,2020-02-18 05:13:00-05:00,DXCM,neutral
393132.0,50 Stocks Moving In Friday's Mid-Day Session,2020-02-14 12:23:00-05:00,DXCM,neutral
393133.0,"CFRA Maintains Hold on DexCom, Raises Price Target to $258",2020-02-14 11:58:00-05:00,DXCM,neutral
393134.0,"Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $300",2020-02-14 10:18:00-05:00,DXCM,neutral
393135.0,Stocks That Hit 52-Week Highs On Friday,2020-02-14 10:15:00-05:00,DXCM,neutral
393136.0,"Oppenheimer Maintains Outperform on DexCom, Raises Price Target to $285",2020-02-14 09:49:00-05:00,DXCM,neutral
393137.0,10 Biggest Price Target Changes For Friday,2020-02-14 08:44:00-05:00,DXCM,neutral
393138.0,DexCom shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.,2020-02-14 08:35:00-05:00,DXCM,positive
393139.0,"The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering",2020-02-14 08:23:00-05:00,DXCM,negative
393140.0,"Raymond James Maintains Outperform on DexCom, Raises Price Target to $288",2020-02-14 07:46:00-05:00,DXCM,neutral
393141.0,"UBS Maintains Neutral on DexCom, Raises Price Target to $275",2020-02-14 07:22:00-05:00,DXCM,neutral
393142.0,30 Stocks Moving in Friday's Pre-Market Session,2020-02-14 07:11:00-05:00,DXCM,neutral
393143.0,"Stephens & Co. Maintains Overweight on DexCom, Raises Price Target to $300",2020-02-14 06:29:00-05:00,DXCM,negative
393144.0,DexCom shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.,2020-02-13 16:27:00-05:00,DXCM,positive
393145.0,DexCom Sees FY20 Sales $1.725B-$1.775B vs $1.77B Estimate,2020-02-13 16:02:00-05:00,DXCM,neutral
393146.0,"DexCom Q4 Adj. EPS $1.15 Beats $0.74 Estimate, Sales $462.8M Beat $442.38M Estimate",2020-02-13 16:01:00-05:00,DXCM,neutral
393147.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,DXCM,negative
393148.0,"Earnings Scheduled For February 13, 2020",2020-02-13 04:27:00-05:00,DXCM,neutral
393149.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-12 11:45:00-05:00,DXCM,neutral
393150.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,DXCM,positive
393151.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-11 10:17:00-05:00,DXCM,neutral
393152.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,DXCM,positive
393153.0,The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight,2020-02-09 15:22:00-05:00,DXCM,neutral
393154.0,Stocks That Hit 52-Week Highs On Friday,2020-01-31 10:23:00-05:00,DXCM,neutral
393155.0,"DexCom Sees Prelim. Q4 Sales ~$457M vs $431.47M Est., Prelim. FY19 Sales $1.47B vs $1.44B Est.; Sees FY20 Sales $1.725B-$1.775B vs $1.75B Est.",2020-01-13 07:34:00-05:00,DXCM,neutral
393156.0,Stocks That Hit 52-Week Highs On Friday,2020-01-10 12:18:00-05:00,DXCM,neutral
393157.0,"The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx",2020-01-10 07:13:00-05:00,DXCM,positive
393158.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-09 15:15:00-05:00,DXCM,neutral
393159.0,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results",2020-01-09 08:39:00-05:00,DXCM,positive
393160.0,"The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results",2020-01-08 08:12:00-05:00,DXCM,positive
393161.0,"JP Morgan Maintains Overweight on DexCom, Raises Price Target to $255",2019-12-20 09:32:00-05:00,DXCM,neutral
393162.0,"UPDATE: Bank Of America On Dexcom Notes 'We do not expect a potential Libre 2 approval to be a major negative with G7 coming, with DXCM winning preferred payer agreements, and with out-of-pocket costs quickly narrowing between G6 and Libre'",2019-12-18 11:43:00-05:00,DXCM,positive
393163.0,"UPDATE: Bank Of America Reiterates Buy On Dexcom, Raises Target To $250, Names A Top Idea For 2020 Notes 'Street estimates remain too low in our view, and the stock likely works into a year-end G7 launch'",2019-12-18 11:43:00-05:00,DXCM,negative
393164.0,"Bank of America Reiterates Buy on DexCom, Raises Price Target to $250",2019-12-18 10:21:00-05:00,DXCM,neutral
393165.0,"DexCom Shares Down 0.2%; BofA Earlier Issued Note Calling Stock 'A top idea for 2020,' Raised Price Target From $220 To $250",2019-12-18 10:06:00-05:00,DXCM,positive
393166.0,"Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $225",2019-12-17 09:02:00-05:00,DXCM,neutral
393167.0,DexCom Says Eli Lilly Will Integrate its Continuous Glucose Monitoring into Lilly's Personalized Diabetes Management System,2019-12-16 06:46:00-05:00,DXCM,neutral
393168.0,Watching shares of DexCom And Insulet After Rival Tandem Received FDA Marketing Authorization For Diabetes Care Control-IQ Technology,2019-12-13 11:56:00-05:00,DXCM,positive
393169.0,"The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend",2019-12-06 07:39:00-05:00,DXCM,positive
393170.0,Stocks That Hit 52-Week Highs On Thursday,2019-12-05 10:16:00-05:00,DXCM,neutral
393171.0,"The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission",2019-12-05 07:14:00-05:00,DXCM,positive
393172.0,Stocks That Hit 52-Week Highs On Wednesday,2019-12-04 10:30:00-05:00,DXCM,neutral
393173.0,"The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug",2019-12-04 07:06:00-05:00,DXCM,negative
393174.0,Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.,2019-12-02 11:31:00-05:00,DXCM,negative
393175.0,Stocks That Hit 52-Week Highs On Friday,2019-11-29 10:28:00-05:00,DXCM,neutral
393176.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-27 10:14:00-05:00,DXCM,neutral
393177.0,"The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen",2019-11-27 07:26:00-05:00,DXCM,negative
393178.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-26 11:03:00-05:00,DXCM,neutral
393179.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,DXCM,positive
393180.0,Stocks That Hit 52-Week Highs On Monday,2019-11-25 10:19:00-05:00,DXCM,neutral
393181.0,"The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon",2019-11-21 07:22:00-05:00,DXCM,positive
393182.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-20 10:12:00-05:00,DXCM,neutral
393183.0,"The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data",2019-11-20 07:25:00-05:00,DXCM,positive
393184.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-19 10:21:00-05:00,DXCM,neutral
393185.0,Stocks That Hit 52-Week Highs On Monday,2019-11-18 11:01:00-05:00,DXCM,neutral
393186.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,DXCM,neutral
393187.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-12 10:11:00-05:00,DXCM,neutral
393188.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,DXCM,neutral
393189.0,These Are The Winners Of The Inaugural WeTrader Paper Trading Competition,2019-11-11 10:53:00-05:00,DXCM,positive
393190.0,Stocks That Hit 52-Week Highs On Monday,2019-11-11 10:15:00-05:00,DXCM,neutral
393191.0,"The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut",2019-11-08 08:14:00-05:00,DXCM,neutral
393192.0,94 Biggest Movers From Yesterday,2019-11-08 06:01:00-05:00,DXCM,neutral
393193.0,Mid-Afternoon Market Update: DexCom Gains Following Strong Q3 Results; Obseva Shares Plunge,2019-11-07 14:09:00-05:00,DXCM,positive
393194.0,Mid-Day Market Update: Crude Oil Up Over 2%; Party City Shares Fall After Downbeat Q3 Results,2019-11-07 12:34:00-05:00,DXCM,positive
393195.0,"Raymond James Maintains Outperform on DexCom, Raises Price Target to $189",2019-11-07 12:29:00-05:00,DXCM,neutral
393196.0,75 Stocks Moving In Thursday's Mid-Day Session,2019-11-07 12:19:00-05:00,DXCM,neutral
393197.0,"Piper Jaffray Maintains Overweight on DexCom, Raises Price Target to $200",2019-11-07 11:51:00-05:00,DXCM,negative
393198.0,"Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $195",2019-11-07 10:52:00-05:00,DXCM,neutral
393199.0,"Stifel Nicolaus Maintains Buy on DexCom, Raises Price Target to $200",2019-11-07 10:41:00-05:00,DXCM,neutral
393200.0,Stocks That Hit 52-Week Highs On Thursday,2019-11-07 10:16:00-05:00,DXCM,neutral
393201.0,"Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $202",2019-11-07 09:30:00-05:00,DXCM,neutral
393202.0,"Baird Maintains Outperform on DexCom, Raises Price Target to $240",2019-11-07 09:03:00-05:00,DXCM,neutral
393203.0,DexCom shares are trading higher after the company reported better-than-expected Q3 results and raised FY19 sales guidance.,2019-11-07 08:21:00-05:00,DXCM,positive
393204.0,23 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-11-07 08:04:00-05:00,DXCM,neutral
393205.0,"JP Morgan Maintains Overweight on DexCom, Raises Price Target to $215",2019-11-07 08:01:00-05:00,DXCM,neutral
393206.0,30 Stocks Moving in Thursday's Pre-Market Session,2019-11-07 07:58:00-05:00,DXCM,neutral
393207.0,"UBS Maintains Neutral on DexCom, Raises Price Target to $185",2019-11-07 07:36:00-05:00,DXCM,neutral
393208.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,DXCM,negative
393209.0,DexCom Raises FY2019 Sales Guidance from $1.325B-1.375B to $1.425B-1.45B,2019-11-06 17:09:00-05:00,DXCM,neutral
393210.0,"DexCom Q3 EPS $0.65 Beats $0.21 Estimate, Sales $396.3M Beat $348.12M Estimate",2019-11-06 17:08:00-05:00,DXCM,neutral
393211.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,DXCM,positive
393212.0,"Stifel Initiates Coverage On DexCom with Buy Rating, Announces $190 Price Target",2019-10-23 06:52:00-04:00,DXCM,neutral
393213.0,DexCom shares are trading lower after the company's competitor Abbott announced a partnership to develop a glucose monitoring system with Tandem Diabetes.,2019-10-15 13:02:00-04:00,DXCM,neutral
393214.0,Dexcom Reports Quentin Blackford Promoted As COO,2019-09-17 16:16:00-04:00,DXCM,positive
393215.0,"Shares of companies in the diagnostics and research space are trading lower, potentially on continued weakness after DexCom provided bearish commentary at a Morgan Stanley healthcare conference on Monday.",2019-09-10 11:22:00-04:00,DXCM,negative
393216.0,DexCom shares are trading lower after the company said it still sees pressure on Q3 comps at the Morgan Stanley Healthcare Conference.,2019-09-09 10:20:00-04:00,DXCM,negative
393217.0,Hearing DexCom At Morgan Stanley Healthcare Conference Says Still Sees Pressure On Q3 Comps,2019-09-09 10:06:00-04:00,DXCM,negative
393218.0,10 Biggest Price Target Changes For Tuesday,2019-09-03 09:12:00-04:00,DXCM,neutral
393219.0,"BMO Capital Maintains Outperform on DexCom, Raises Price Target to $190",2019-09-03 07:43:00-04:00,DXCM,neutral
393220.0,"Baird Maintains Outperform on DexCom, Raises Price Target to $195",2019-08-29 09:09:00-04:00,DXCM,neutral
393221.0,Stocks That Hit 52-Week Highs On Tuesday,2019-08-27 10:30:00-04:00,DXCM,neutral
393222.0,Court Rules That Patents Asserted Against Dexcom CGM Systems Are Invalid,2019-08-23 16:26:00-04:00,DXCM,neutral
393223.0,Stocks That Hit 52-Week Highs On Friday,2019-08-23 10:33:00-04:00,DXCM,neutral
393224.0,Stocks That Hit 52-Week Highs On Thursday,2019-08-22 10:32:00-04:00,DXCM,neutral
393225.0,"The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study",2019-08-22 07:18:00-04:00,DXCM,positive
393226.0,Stocks That Hit 52-Week Highs On Wednesday,2019-08-21 10:17:00-04:00,DXCM,neutral
393227.0,"The Daily Biotech Pulse: Ra Pharma Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform",2019-08-21 07:40:00-04:00,DXCM,neutral
393228.0,Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.,2019-08-19 12:31:00-04:00,DXCM,positive
393229.0,Stocks That Hit 52-Week Highs On Monday,2019-08-19 10:53:00-04:00,DXCM,neutral
393230.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,DXCM,negative
393231.0,Stocks That Hit 52-Week Highs On Friday,2019-08-16 10:35:00-04:00,DXCM,neutral
393232.0,"Shares of several healthcare companies are trading lower in sympathy with the overall market after the spread between the 2-year and 10-year yield curve inverted for the first time since 2007, potentially signaling an oncoming recession.",2019-08-14 11:17:00-04:00,DXCM,negative
393233.0,ï»¿Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.,2019-08-13 11:53:00-04:00,DXCM,positive
393234.0,DexCom shares are trading higher on seemingly no company-specific news.,2019-08-08 14:11:00-04:00,DXCM,neutral
393235.0,"Shares of diagnostics and research companies are trading higher in sympathy with Syneos Health, which reported strong Q2 results and raised FY19 guidance.",2019-08-06 13:54:00-04:00,DXCM,positive
393236.0,"Bank of America Maintains Buy on DexCom, Raises Price Target to $185",2019-08-01 11:42:00-04:00,DXCM,neutral
393237.0,"Baird Maintains Outperform on DexCom, Raises Price Target to $186",2019-08-01 09:47:00-04:00,DXCM,neutral
393238.0,"UBS Maintains Neutral on DexCom, Raises Price Target to $160",2019-08-01 08:30:00-04:00,DXCM,neutral
393239.0,"Raymond James Maintains Outperform on DexCom, Raises Price Target to $172",2019-08-01 07:29:00-04:00,DXCM,neutral
393240.0,DexCom shares are trading lower despite the company reporting strong Q2 earnings.,2019-07-31 16:17:00-04:00,DXCM,positive
393241.0,Dexcom Raises FY19 Sales Guidance From $1.25B-$1.3B To $1.325B-$1.375B vs $1.29B Estimate,2019-07-31 16:15:00-04:00,DXCM,neutral
393242.0,"DexCom Q2 EPS $0.08 Beats $0.01 Estimate, Sales $336.4M Beat $307.04M Estimate",2019-07-31 16:14:00-04:00,DXCM,neutral
393243.0,Stocks That Managed to Breach 52-Week Highs Wednesday Morning,2019-07-31 11:01:00-04:00,DXCM,neutral
393244.0,"The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster",2019-07-31 07:06:00-04:00,DXCM,negative
393245.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,DXCM,negative
393246.0,DexCom Shares Do Not Appear To Be Impacted Following Earlier Article Highlighting Possible Competitor In Diabetes Space 'Apple continues expanding into health care by selling its first diabetes product in stores',2019-06-27 11:55:00-04:00,DXCM,positive
393247.0,DexCom Shares Closed Up Nearly 10% On Mon.; Piper Jaffray Analyst JP McKim Tells Benzinga Upside Attributed To 'Positive Developments At The American Diabetes Association',2019-06-11 11:04:00-04:00,DXCM,positive
393248.0,DexCom shares are trading higher on elevated volume. Not seeing any fundamental news to justify price action.,2019-06-10 14:04:00-04:00,DXCM,positive
393249.0,"Dexcom Shares Volatile Over Last Few Mins. Following Senseonics FDA Doc On Eversense, Very Large Volume Spike As Doc Was Circulated By Traders; Piper Jaffray Noted Co. Also Has A Non-Adjunctive Claim",2019-06-06 15:27:00-04:00,DXCM,positive
393250.0,"Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.",2019-05-14 13:32:00-04:00,DXCM,positive
393251.0,"Jim Cramer Weighs In On CVS, Starbucks, Tilray And More",2019-05-08 07:45:00-04:00,DXCM,neutral
393252.0,"Shares of companies in the diagnostics and research space are trading higher in sympathy with Bruker, which reported better-than-expected Q1 EPS and sales results.",2019-05-03 13:21:00-04:00,DXCM,positive
393253.0,"BMO Capital Maintains Outperform on DexCom, Inc. - Common Stock, Raises Price Target to $172",2019-05-02 10:37:00-04:00,DXCM,neutral
393254.0,DexCom shares are trading higher after the company reported better-than-expected Q1 financial results and announced 2019 EPS guidance above the analyst consensus estimate.,2019-05-02 09:47:00-04:00,DXCM,positive
393255.0,"Raymond James Maintains Outperform on DexCom, Inc. - Common Stock, Lowers Price Target to $150",2019-05-02 07:53:00-04:00,DXCM,negative
393256.0,Dexcom Guides FY19 Revenues Of $1.25-1.3B Vs. $1.23B Estimate,2019-05-01 16:48:00-04:00,DXCM,neutral
393257.0,"DexCom Q1 EPS $(0.05) May Not Compare To $(0.16) Estimate, Sales $280.5M Beat $246.39M Estimate",2019-05-01 16:47:00-04:00,DXCM,neutral
393258.0,DexCom Q1 Earnings Preview,2019-05-01 11:46:00-04:00,DXCM,neutral
393259.0,"UBS Maintains Neutral on DexCom, Inc. - Common Stock, Lowers Price Target to $140",2019-04-30 08:46:00-04:00,DXCM,negative
393260.0,"Jim Cramer Gives His Opinion On Sarepta, Blackstone, Tractor Supply And More",2019-04-26 07:57:00-04:00,DXCM,neutral
393261.0,Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.,2019-04-17 10:38:00-04:00,DXCM,positive
393262.0,DexCom shares are trading higher. Not currently seeing any company-specific news.,2019-04-10 13:15:00-04:00,DXCM,positive
393263.0,60 Biggest Movers From Friday,2019-03-25 05:42:00-04:00,DXCM,neutral
393264.0,41 Stocks Moving In Friday's Mid-Day Session,2019-03-22 12:30:00-04:00,DXCM,neutral
393265.0,DexCom shares trading lower following a nearly 3 percent decline on Thursday amid a negative report from Spruce Point. Shares traded below the $140 level Friday.,2019-03-22 10:23:00-04:00,DXCM,negative
393266.0,Spruce Point: Dexcom Could Fall 45-60%,2019-03-21 15:46:00-04:00,DXCM,neutral
393267.0,Spruce Point Sees 60% Downside In Dexcom (approximately $65-$85/Share),2019-03-21 13:07:00-04:00,DXCM,negative
393268.0,'Amazon-exclusive medical brand Choice expands services with One Drop partnership' -Digiday Reported On Tuesday,2019-03-21 10:36:00-04:00,DXCM,negative
393269.0,Hearing Hedgeye Sees Over 305 Downside In Dexcom; Likes Co. And Its Products But Believe Stock Has 'Gotten Ahead Of Itself',2019-03-05 14:28:00-05:00,DXCM,positive
393270.0,Dexcom Discussed As New Short Idea By Hedgeye,2019-03-05 14:16:00-05:00,DXCM,neutral
393271.0,'Diabetes-tech giant Dexcom plans to lay off 13% of its workers and outsource jobs. People who rely on the products say it's endangering a key part of its business.' -Business Insider Earlier Reported,2019-03-05 12:06:00-05:00,DXCM,neutral
393272.0,"US Senator Ron Wyden Says Finance Committee Continuing To Investigate How Major Insulin Manufacturers Set, Increase 'Outrageous Price Of Insulin'",2019-03-04 12:28:00-05:00,DXCM,negative
393273.0,"Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $160",2019-02-25 10:27:00-05:00,DXCM,neutral
393274.0,"DexCom Q4 Adj. EPS $0.54 May Not Compare To $0.17 Estimate, Sales $338M Beat $299.67M Estimate",2019-02-21 17:23:00-05:00,DXCM,neutral
393275.0,"The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan",2019-02-21 07:32:00-05:00,DXCM,positive
393276.0,"The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings",2019-02-15 14:00:00-05:00,DXCM,neutral
393277.0,"Jim Cramer Gives His Opinion On Cleveland-Cliffs, SINA, Take-Two And More",2019-01-11 08:23:00-05:00,DXCM,neutral
393278.0,DexCom shares are trading higher after the company announced it expects preliminary Q4 sales to have increased 50% since last year.,2019-01-07 09:56:00-05:00,DXCM,positive
393279.0,DexCom Sees FY2019 Sales $1.18B-1.23B vs $1.18B Est,2019-01-07 07:45:00-05:00,DXCM,neutral
393280.0,DexCom,2019-01-07 07:45:00-05:00,DXCM,neutral
393281.0,DexCom,2019-01-07 07:44:00-05:00,DXCM,neutral
393282.0,"Morgan Stanley Maintains Equal-Weight on DexCom, Lowers Price Target to $135",2019-01-02 10:28:00-05:00,DXCM,negative
393283.0,DexCom Option Alert: Fri $120 Calls Sweep (2) near the Ask: 540 @ $1.75 vs 283 OI; Ref=$116.85,2018-12-19 11:04:00-05:00,DXCM,positive
393284.0,Health insurers and healthcare providers are trading down today after a Texas court ruled that ObamaCare was unconstitutional.,2018-12-17 11:06:00-05:00,DXCM,neutral
393285.0,"UBS Initiates Coverage On DexCom with Neutral Rating, Announces $135 Price Target",2018-11-28 07:59:00-05:00,DXCM,neutral
393286.0,"The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO",2018-11-21 08:04:00-05:00,DXCM,negative
393287.0,"DexCom, Inc. Q3 EPS $0.17, Sales $266.7M Beat $241.3M Estimate",2018-11-06 16:06:00-05:00,DXCM,neutral
393288.0,DexCom Raises FY18 Sales Guidance From $925M To $975M vs $930.8M Estimate,2018-11-06 16:03:00-05:00,DXCM,neutral
393289.0,"DexCom, Inc. Q3 EPS $0.17 Beats $(0.10) Estimate, Sales $266.7M Beat $241.3M Estimate",2018-11-06 16:03:00-05:00,DXCM,neutral
393290.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,DXCM,positive
393291.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,DXCM,neutral
393292.0,"Benzinga's Top Upgrades, Downgrades For October 19, 2018",2018-10-19 09:17:00-04:00,DXCM,positive
393293.0,"Goldman Sachs Upgrades DexCom to Neutral, Announces $125 Price Target",2018-10-19 06:02:00-04:00,DXCM,neutral
393294.0,Dexcom Announces G6 Continuous Glucose Monitoring System Will Be Available To Medicare Beneficiaries With Diabetes In Early 2019,2018-10-18 08:05:00-04:00,DXCM,positive
393295.0,"Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $150",2018-10-11 09:13:00-04:00,DXCM,neutral
393296.0,Novo Nordisk Announces First Global Launch Of Connected Insulin Pens,2018-10-01 05:00:00-04:00,DXCM,neutral
393297.0,"Jim Cramer Gives His Opinion on McDonald's, PayPal And More",2018-09-18 11:13:00-04:00,DXCM,neutral
393298.0,"Once Again, Baird Predicts End To Tandem's 'Fantastic' Run",2018-09-14 10:24:00-04:00,DXCM,neutral
393299.0,"Stocks Which Set New 52-Week High Yesterday, September 13th",2018-09-14 09:26:00-04:00,DXCM,neutral
393300.0,"Stocks Which Set New 52-Week High Yesterday, September 11th",2018-09-12 12:17:00-04:00,DXCM,neutral
393301.0,"Benzinga's Top Upgrades, Downgrades For September 12, 2018",2018-09-12 09:15:00-04:00,DXCM,positive
393302.0,Northland Securities Upgrades DexCom to Market Perform,2018-09-12 08:34:00-04:00,DXCM,positive
393303.0,"Stocks Which Set New 52-Week High Friday, September 7th",2018-09-10 16:36:00-04:00,DXCM,neutral
393304.0,"Stocks Which Set New 52-Week High Yesterday, September 4th",2018-09-05 10:22:00-04:00,DXCM,neutral
393305.0,"The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results",2018-09-05 08:28:00-04:00,DXCM,positive
393306.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,DXCM,neutral
393307.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,DXCM,neutral
393308.0,"Stocks Which Set New 52-Week High Yesterday, August 23rd",2018-08-24 09:11:00-04:00,DXCM,neutral
393309.0,"The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict",2018-08-24 08:47:00-04:00,DXCM,positive
393310.0,"Stocks Which Set New 52-Week High Yesterday, August 22nd",2018-08-23 10:51:00-04:00,DXCM,neutral
393311.0,10 Biggest Price Target Changes For Thursday,2018-08-23 10:20:00-04:00,DXCM,neutral
393312.0,"The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero",2018-08-23 08:23:00-04:00,DXCM,negative
393313.0,"Baird Maintains Outperform on DexCom, Raises Price Target to $160",2018-08-23 08:06:00-04:00,DXCM,neutral
393314.0,"Stephens & Co. Maintains Overweight on DexCom, Raises Price Target to $160",2018-08-23 07:49:00-04:00,DXCM,negative
393315.0,"Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $150",2018-08-23 07:31:00-04:00,DXCM,neutral
393316.0,"Dexcom To Acquire TypeZero Tech, No Financial Terms Disclosed",2018-08-22 16:05:00-04:00,DXCM,negative
393317.0,"Stocks Which Set New 52-Week High Yesterday, August 21st",2018-08-22 09:06:00-04:00,DXCM,neutral
393318.0,"The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin",2018-08-22 08:20:00-04:00,DXCM,negative
393319.0,"Stocks Which Set New 52-Week High Tues., Aug. 21, 2018",2018-08-21 14:50:00-04:00,DXCM,neutral
393320.0,"The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows",2018-08-21 08:40:00-04:00,DXCM,positive
393321.0,"Stocks Which Set New 52-Week High Yesterday, August 15th",2018-08-16 10:22:00-04:00,DXCM,neutral
393322.0,"Stocks Which Set New 52-Week High Yesterday, August 14th",2018-08-15 12:29:00-04:00,DXCM,neutral
393323.0,"Bank of America Maintains Buy on DexCom, Raises Price Target to $145",2018-08-15 09:17:00-04:00,DXCM,neutral
393324.0,"The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue",2018-08-15 08:48:00-04:00,DXCM,negative
393325.0,"Stocks Which Set New 52-Week High Yesterday, August 6th",2018-08-07 11:27:00-04:00,DXCM,neutral
393326.0,Berenberg Upgrades DexCom to Buy,2018-08-06 08:47:00-04:00,DXCM,neutral
393327.0,"Stocks Which Set New 52-Week High Yesterday, August 2nd",2018-08-03 11:16:00-04:00,DXCM,neutral
393328.0,10 Biggest Price Target Changes For Friday,2018-08-03 09:58:00-04:00,DXCM,neutral
393329.0,DexCom shares are trading down 3.5% despite strong Q2 results reported Wednesday and positive analyst activity over past two days.,2018-08-03 09:42:00-04:00,DXCM,positive
393330.0,"Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $130",2018-08-03 07:16:00-04:00,DXCM,neutral
393331.0,75 Biggest Movers From Yesterday,2018-08-03 06:10:00-04:00,DXCM,neutral
393332.0,Mid-Afternoon Market Update: Crude Oil Up Over 2%; Boingo Wireless Shares Spike Higher,2018-08-02 14:41:00-04:00,DXCM,negative
393333.0,65 Stocks Moving In Thursday's Mid-Day Session,2018-08-02 12:26:00-04:00,DXCM,neutral
393334.0,"Jefferies Maintains Buy on DexCom, Raises Price Target to $125",2018-08-02 10:49:00-04:00,DXCM,neutral
393335.0,"Bank of America Maintains Buy on DexCom, Raises Price Target to $127",2018-08-02 10:42:00-04:00,DXCM,neutral
393336.0,"Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $125",2018-08-02 10:42:00-04:00,DXCM,neutral
393337.0,Mid-Morning Market Update: Markets Open Lower; Aetna Profit Beats Expectations,2018-08-02 10:17:00-04:00,DXCM,positive
393338.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,DXCM,positive
393339.0,"BMO Capital Maintains Outperformer on DexCom, Raises Price Target to $125",2018-08-02 08:45:00-04:00,DXCM,neutral
393340.0,Benzinga Pro's 5 Stocks To Watch Today,2018-08-02 08:44:00-04:00,DXCM,neutral
393341.0,32 Stocks Moving In Thursday's Pre-Market Session,2018-08-02 08:05:00-04:00,DXCM,neutral
393342.0,"DexCom Shares Gain20% After Hours; Co. Beat Q2 EPs And Sales Estimates, Raised FY18 Sales Guidance Above Estimates",2018-08-01 17:37:00-04:00,DXCM,positive
393343.0,"DexCom Executive Chairman and Director Terry Gregg Retires, President and CEO Kevin Sayer Appointed Chairman of the Board",2018-08-01 16:11:00-04:00,DXCM,neutral
393344.0,DexCom Raises FY18 Sales Outlook From $850-$860M To $925M vs $862.25M Est.,2018-08-01 16:05:00-04:00,DXCM,neutral
393345.0,"DexCom Q2 Adj. EPS $(0.10) Beats $(0.18) Estimate, Sales $242.5M Beat $205.68M Estimate",2018-08-01 16:04:00-04:00,DXCM,neutral
393346.0,'A New Revolution Of Medicine': Senseonics Brings Automation To Diabetes Care,2018-07-16 15:09:00-04:00,DXCM,positive
393347.0,"Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering",2018-07-13 08:34:00-04:00,DXCM,neutral
393348.0,"Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial",2018-07-12 08:37:00-04:00,DXCM,neutral
393349.0,DexCom Shares Up 2% Following Earlier Upgrade From Market Perform To Outperform At Raymond James,2018-07-02 09:59:00-04:00,DXCM,positive
393350.0,"Benzinga's Top Upgrades, Downgrades For July 2, 2018",2018-07-02 09:21:00-04:00,DXCM,positive
393351.0,"The Market In 5 Minutes: More Trade Threats, July PDUFA Dates, Tesla's Goal And More",2018-07-02 09:00:00-04:00,DXCM,negative
393352.0,"William Blair Growth Stock Conference Begins Today, Presenters Include: Aspen Technology, Ellie Mae, FleetCor, Catalent, SendGrid, DexCom, Discover Financial, and Okta",2018-06-12 07:16:00-04:00,DXCM,positive
393353.0,Dexcom Reports Co. Received CE Mark For Dexcom G6 System For People With Diabetes Ages 2 Years And Up,2018-06-12 07:08:00-04:00,DXCM,neutral
393354.0,"Andrew Left Goes Long Fitbit, Sees 130% Upside",2018-06-11 15:33:00-04:00,DXCM,neutral
393355.0,30 Stocks Moving In Friday's Mid-Day Session,2018-06-08 12:31:00-04:00,DXCM,neutral
393356.0,"The Market In 5 Minutes: China, ZTE, McDonald's And More",2018-06-08 09:00:00-04:00,DXCM,neutral
393357.0,"Benzinga's Top Upgrades, Downgrades For June 8, 2018",2018-06-08 08:58:00-04:00,DXCM,positive
393358.0,A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street,2018-06-08 06:55:00-04:00,DXCM,negative
393359.0,CORRECTION: JP Morgan Upgrades DexCom to Overweight,2018-06-08 06:14:00-04:00,DXCM,neutral
393361.0,Dexcom Shares Down 4.2% Thurs.; Traders Attributing Weakness To Earlier Circulation Apple Planning Device To Help Monitor Blood Pressure,2018-06-07 12:09:00-04:00,DXCM,neutral
393362.0,Piper Jaffray: Tandem Diabetes Is Entering A 'Goldilocks Period',2018-05-14 14:59:00-04:00,DXCM,neutral
393363.0,"Bank of America Initiates Coverage On DexCom with Buy Rating, Announces $100 Price Target",2018-05-11 09:11:00-04:00,DXCM,neutral
393364.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,DXCM,neutral
393365.0,55 Biggest Movers From Yesterday,2018-05-04 04:41:00-04:00,DXCM,neutral
393366.0,DexCom Raises FY18 Outlook From $830M-$850M To $850M-$860M vs $842.79M Est.,2018-05-02 16:46:00-04:00,DXCM,neutral
393367.0,"DexCom Q1 Adj. EPS $(0.32) Beats $(0.33) Est., Sales $184.40M Beats $172.08M Est.",2018-05-02 16:44:00-04:00,DXCM,neutral
393368.0,Guggenheim Initiates Coverage On DexCom with Neutral Rating,2018-04-04 09:12:00-04:00,DXCM,neutral
393369.0,"Goldman Sachs Initiates Coverage On DexCom with Sell Rating, Announces $57.00 Price Target",2018-04-04 08:36:00-04:00,DXCM,neutral
393370.0,"Benzinga's Top Analyst Calls From March 29, 2018",2018-03-29 11:25:00-04:00,DXCM,positive
393371.0,"BMO Increases DexCom Price Target From $68 To $78 And Reiterates Their Outperform Rating As Co. Received G6 CGM FDA Approval Ahead Of Schedule; Believes Approval Gives Co. Momentum And Awaits An Update On Product Pricing, Guidance On Q1 Earnings Call",2018-03-29 10:05:00-04:00,DXCM,positive
393372.0,28 Stocks Moving In Wednesday's Pre-Market Session,2018-03-28 08:19:00-04:00,DXCM,neutral
393373.0,DexCom Shares Indicated Up 3.5% Near Tues. High Around $72.50; A Co. Press Release Tues. Evening Confirmed Marketing Authorization For Co.'s New G6 CGM System,2018-03-28 06:27:00-04:00,DXCM,positive
393374.0,"DexCom Shares Spike ~$0.50 As Traders Circulate FDA.gov Alert Showing Approval For G6 iCGM System For Determining Sugar Levels In Children 2+, Adults With Diabetes",2018-03-27 15:20:00-04:00,DXCM,positive
393375.0,Baird Upgrades DexCom to Outperform,2018-03-23 07:23:00-04:00,DXCM,neutral
393376.0,"WaveForm  Receives Favorable Decision On Glucose Monitoring Patents, PTAB Haqs Ruled Two Early Patents Held By WaveForm Are Not Invalid; Watch For Downside In Dexcom",2018-03-08 13:38:00-05:00,DXCM,positive
393377.0,"DexCom Reports Q4 EPS $0.10 vs. $0.03 Est., Sales $221M vs. $$215.87M Est.",2018-02-27 16:02:00-05:00,DXCM,neutral
393378.0,DexCom Q4 Earnings Preview,2018-02-27 12:29:00-05:00,DXCM,neutral
393379.0,Weakness In Dexcom Being Attributed To New Coverage Policy From Cigna That Cover Abbott's Libre Glucose Monitoring System,2018-01-18 11:36:00-05:00,DXCM,negative
393380.0,"UnitedHealthcare, Dexcom Report Will Bring Wearable Technology Solution, 1-on-1 Coaching To People Battling Type-2 Diabetes",2018-01-10 10:01:00-05:00,DXCM,positive
393381.0,"DexCom Shares Down 3.048%; Earlier Co. Presented At JP Morgan Health Care Conf., Reported FY18 Outlook, Sees Sales $830M-$850M vs $853.06M Est.",2018-01-09 14:13:00-05:00,DXCM,positive
393382.0,"JP Morgan Healthcare Conference Continues Today, Presenters Include: Bluebird Bio, Agilent, Insulet, Cigna, DexCom, Eli Lilly, LifePoint, Acadia, Alkermes, Juno Therapeutics",2018-01-09 09:02:00-05:00,DXCM,positive
393383.0,DexCom Sees FY18 Sales ~$830M-$850M vs $854.6M Est.,2018-01-08 16:06:00-05:00,DXCM,neutral
393384.0,DexCom Sees Q4 Sales ~$218M vs $212.7M Est.; FY17 Sales ~$715M vs $710.2M Est.,2018-01-08 16:05:00-05:00,DXCM,neutral
393385.0,36 Biggest Movers From Yesterday,2018-01-05 05:48:00-05:00,DXCM,neutral
393386.0,"Dexcom Shares Down 8%, Potentially Following News Abbott's CGM System, FreeStyle Libre Is Now Available To Medicare Patients; Northland Issued Mid-Day Downgrade On Stock",2018-01-04 13:19:00-05:00,DXCM,positive
393387.0,Northland Securities Downgrades DexCom to Underperform,2018-01-04 11:13:00-05:00,DXCM,positive
393388.0,Dexcom Shares Ticking Lower As Hearing Northland Issued Mid-Day Downgrade On Stock,2018-01-04 11:11:00-05:00,DXCM,neutral
393389.0,"DexCom 13G From Wellington Mgmt. Group Shows Raised Stake From ~7.97M Shares To ~8.7M Shares, Or 10.05% Stake",2017-12-11 11:03:00-05:00,DXCM,positive
393390.0,"Piper Jaffray Healthcare Conference Concludes Today, Presenters Include: Kadmon, Ignyta, Eagle Pharmaceuticals, Tandem Diabetes Care, DexCom, and Alnylam Pharmaceuticals",2017-11-29 09:30:00-05:00,DXCM,positive
393391.0,Dexcom Reports Development Agreement with Lilly to Integrate Dexcom CGM into Connected Diabetes Ecosystem,2017-11-21 10:33:00-05:00,DXCM,positive
393392.0,"PPG, Dexcom Shares Ticking Modestly Higher Here Amid Report Out Of Chatroom Co.'s Will Be Featured On CNBC's 'Mad Money'",2017-11-16 11:02:00-05:00,DXCM,negative
393393.0,"DexCom Q3 Adj. EPS $(0.04) vs $(0.16) Est., Sales $184.6M vs $184.2M Est.",2017-11-01 16:38:00-04:00,DXCM,neutral
393394.0,DexCom's Quiet Consolidation After Huge Decline,2017-10-09 13:26:00-04:00,DXCM,positive
393395.0,16 Stocks Moving In Friday's Pre-Market Session,2017-09-29 09:02:00-04:00,DXCM,neutral
393396.0,Mid-Afternoon Market Update: AngioDynamics Drops On Earnings Miss; Zynerba Pharmaceuticals Shares Spike Higher,2017-09-28 15:07:00-04:00,DXCM,positive
393397.0,18 Biggest Mid-Day Losers For Thursday,2017-09-28 13:09:00-04:00,DXCM,negative
393398.0,Canaccord Sticks With Dexcom As Shares Tumble Amid Unexpected Label Addition,2017-09-28 12:58:00-04:00,DXCM,positive
393399.0,Mid-Day Market Update: Exa Corp Rises On Acquisition News; Comtech Shares Plunge,2017-09-28 12:08:00-04:00,DXCM,positive
393400.0,Mid-Morning Market Update: Markets Edge Lower; BlackBerry Tops Q2 Expectations,2017-09-28 10:32:00-04:00,DXCM,positive
393401.0,Canaccord Stick With Buy Rating On Dexcom Following Abbott's Libre Receiving Unexpected Label Addition To Include Insulin Dosing Indication,2017-09-28 09:56:00-04:00,DXCM,neutral
393402.0,5 Biggest Price Target Changes For Thursday,2017-09-28 09:27:00-04:00,DXCM,neutral
393403.0,"Benzinga's Top Upgrades, Downgrades For September 28, 2017",2017-09-28 09:08:00-04:00,DXCM,positive
393404.0,20 Stocks Moving In Thursday's Pre-Market Session,2017-09-28 08:35:00-04:00,DXCM,neutral
393405.0,Tandem Diabetes Reports 1/3 Of t:slim X2 Pump Users Already Updated Their Pumps Via Personal Computer To Add New Dexcom G5 CGM Integration,2017-09-28 08:34:00-04:00,DXCM,neutral
393406.0,The Market In 5 Minutes: The Market Wakes Up To The Trump Tax Plan,2017-09-28 08:25:00-04:00,DXCM,neutral
393407.0,"Dexcom Shares Fall 22% Premarket Following FDA Approval of Abbott's Blood Glucose Monitoring Device, Analyst Downgrades",2017-09-28 07:43:00-04:00,DXCM,positive
393408.0,Raymond James Downgrades DexCom to Market Perform,2017-09-28 06:46:00-04:00,DXCM,neutral
393409.0,JP Morgan Downgrades DexCom to Neutral,2017-09-28 06:17:00-04:00,DXCM,positive
393410.0,"Hearing Northland Securities Initiates Coverage On DexCom with Outperform Rating, Announces $85.00 Price Target",2017-09-26 10:03:00-04:00,DXCM,positive
393411.0,"Benzinga's Top Upgrades, Downgrades For September 15, 2017",2017-09-15 09:29:00-04:00,DXCM,positive
393412.0,"Barclays Initiates Coverage On DexCom with Equal-Weight Rating, Announces $76.00 Price Target",2017-09-15 07:11:00-04:00,DXCM,neutral
393413.0,Fitbit Tracking Higher After Deal With Dexcom,2017-09-08 09:43:00-04:00,DXCM,neutral
393414.0,"Fitbit, Dexcom to Develop Continuous Glucose Monitoring Experience for People Living with Diabetes",2017-09-07 09:01:00-04:00,DXCM,neutral
393415.0,DexCom Reports Publication Of New Study Showing People With Type-2 Diabetes On MDI Insulin Therapy Benefit From Use Of CGM: 'Participants in the study achieved significant A1C reduction...',2017-08-21 17:01:00-04:00,DXCM,positive
393416.0,"Wedbush PacGrow Healthcare Conference Begins Today, Presenters Include: Omeros, Bovie Medical, Bluebird Bio, Juno Therapeutics, DexCom, Tandem Diabetes, and Insulet",2017-08-15 08:40:00-04:00,DXCM,neutral
393417.0,"DexCom Names Quentin Blackford CFO Effective September 1, 2017",2017-08-01 16:18:00-04:00,DXCM,positive
393418.0,"DexComn Reports Adj. EPS $(0.16) vs $(0.21) Est., Sales $170.6M vs $166.3M Est.",2017-08-01 16:18:00-04:00,DXCM,neutral
393419.0,"Dexcom Reports Q2 Loss/Share $(0.16) vs. $(0.21) Est., Sales $170.6M vs. $166.3M Est.",2017-08-01 16:15:00-04:00,DXCM,neutral
393420.0,DexCom Reports FDA Approval of G5 Mobile App for Android Devices,2017-06-07 08:01:00-04:00,DXCM,positive
393421.0,DexCom Shares Now Up 3.3%,2017-06-05 13:29:00-04:00,DXCM,positive
393422.0,DexCom Shares Spike Higher as Co. Named During Apple Watch Presentation at WWDC,2017-06-05 13:29:00-04:00,DXCM,positive
393423.0,"PiperJaffray Reinstates Overweight on DexCom, Announces $78.00",2017-05-22 07:19:00-04:00,DXCM,negative
393424.0,Benzinga's Option Alert Recap From May 16,2017-05-16 16:59:00-04:00,DXCM,positive
393425.0,Option Alert: Dexcom Jun 70.0 Puts: 500 @  Above Ask!  $2.85: 1305 traded vs 1384 OI:  Earnings 8/1 After Close (est)  $69.65 Ref,2017-05-16 13:44:00-04:00,DXCM,positive
393426.0,BTIG Research Downgrades DexCom to Neutral,2017-05-03 06:57:00-04:00,DXCM,neutral
393427.0,"DexCom Reports Q1 EPS $(0.49) vs $(0.50) Est., Sales $142.3M vs $144.47M Est.",2017-05-02 16:05:00-04:00,DXCM,neutral
393428.0,"Benzinga's Top Upgrades, Downgrades For April 27, 2017",2017-04-27 09:24:00-04:00,DXCM,positive
393429.0,William Blair Initiates Coverage On DexCom with Outperform Rating,2017-04-27 08:58:00-04:00,DXCM,neutral
393430.0,"Barclays Global Healthcare Conference Concludes Today; Presenters Include DexCom, NantKwest, Juno, Humana, And Ironwood Pharma",2017-03-16 08:36:00-04:00,DXCM,neutral
393431.0,"Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio",2017-03-07 08:59:00-05:00,DXCM,neutral
393432.0,"Raymond James Institutional Investors Conference Begins Today; Presenters Include Ruth's Hospitality, DexCom, MAYCOM, Rayonier, TD Ameritrade, & Envision Healthcare",2017-03-06 08:18:00-05:00,DXCM,neutral
393433.0,"DexCom Reports Q4 EPS $(0.09) vs $(0.10) Est., Sales $171.2M vs $167.97M Est.",2017-02-28 16:23:00-05:00,DXCM,neutral
393434.0,"DexCom Diamond 2 Results Positive, Or At Least Not As Bad As Expected",2017-02-16 16:09:00-05:00,DXCM,positive
393435.0,"Downside in Dexcom Shares Intensifies as $82 Level Support Level Breaks; Shares Down 1.3% Over Last Few Mins, Down 2.7% for Session, Down 4.3% Since Open",2017-02-16 10:52:00-05:00,DXCM,positive
393436.0,Dexcom Shares Tick Below $83 Level Over Last Few Mins as Hearing Piper Jaffray Negative on Name,2017-02-16 09:57:00-05:00,DXCM,negative
393437.0,Baillie Gifford Reports 7.25% Passive Stake In Dexcom,2017-01-20 10:21:00-05:00,DXCM,positive
393438.0,DexCom Jumps 25% As It Becomes Only Continuous Glucose Monitoring With Medicare Coverage,2017-01-13 16:12:00-05:00,DXCM,neutral
393439.0,Mid-Afternoon Market Update: Dow Turns Negative; Sanchez Energy Shares Spike Higher,2017-01-13 14:36:00-05:00,DXCM,negative
393440.0,Technical Alert: Dexcom Leaps After Raised Q4 Guidance,2017-01-13 09:55:00-05:00,DXCM,positive
393441.0,"DexCom Sees Prelim. Q4 Rev. ~$168M vs. Est. $167M, FY16 Rev. ~$570M vs. Est. $569M; FY17 Rev. $710-$740M vs. Est. $753M",2017-01-10 08:31:00-05:00,DXCM,neutral
393442.0,"JP Morgan Healthcare Conf. Continues Today; Presenters Include Cooper Companies, Mckesson, Dexcom, CVS, Bristol-Myers, & NanoString",2017-01-10 08:07:00-05:00,DXCM,positive
393443.0,"Morgan Stanley Downgrades DexCom to Neutral, Lowers price target to $66.00",2017-01-03 07:32:00-05:00,DXCM,negative
393444.0,FDA Approval of Dexcom's Non-Adjunctive Indication Triggers a New Era in Diabetes Management,2016-12-20 16:04:00-05:00,DXCM,positive
393445.0,Traders Attributing Recent Strength In Dexcom To FDA Release Highlighting Approval Of Dexcom's G5 Mobile Continuous Glucose Monitoring System Non-Adjunctive Label Claim,2016-12-20 14:28:00-05:00,DXCM,positive
393446.0,15 Biggest Mid-Day Gainers For Monday,2016-12-19 12:43:00-05:00,DXCM,neutral
393447.0,"Benzinga's Top Upgrades, Downgrades For December 19, 2016",2016-12-19 09:08:00-05:00,DXCM,positive
393448.0,"Oppenheimer Upgrades DexCom to Outperform, Maintains $84.00 Target",2016-12-19 07:49:00-05:00,DXCM,neutral
393449.0,B. Riley Upgrades DexCom to Buy,2016-12-15 06:02:00-05:00,DXCM,neutral
393450.0,SkyTides: Insulet's President Provided 'Critical Misinformation To Investors',2016-12-02 11:01:00-05:00,DXCM,negative
393451.0,New Report Questions Insulet Management's 'Baseless' Claims: 'Investors Being Led To The Slaughter',2016-11-29 10:16:00-05:00,DXCM,neutral
393452.0,"PiperJaffray Healthcare Conference Begins Today, Day 1 of 2; Presenters Include NantKwest, Ignyta, Gilead Sciences, DexCom, Incyte, bluebird bio",2016-11-29 08:53:00-05:00,DXCM,neutral
393453.0,"Exclusive: Dexcom CEO Talks Health Canada Approval, International Markets, Investments And Competition",2016-11-17 09:07:00-05:00,DXCM,positive
393454.0,8 Stocks That Rallied Three Days On Increasing Volume,2016-11-16 05:30:00-05:00,DXCM,neutral
393455.0,JP Morgan Says DexCom Data Over The Weekend Was 'Way Above' Expectations,2016-11-14 09:53:00-05:00,DXCM,positive
393456.0,Dexcom Reports Health Canada Approval for G5 Mobile CGM System,2016-11-14 09:51:00-05:00,DXCM,positive
393457.0,18 Biggest Mid-Day Losers For Wednesday,2016-11-02 13:14:00-04:00,DXCM,negative
393458.0,Dexcom Shares Spike to High of $65.25 Following Positive Jim Cramer/CNBC Mention,2016-11-02 09:37:00-04:00,DXCM,positive
393459.0,"Dexcom -19.78% Premarket @$62.51 Following Tuesday's Earnings Miss, Multiple PT Cuts by Analysts",2016-11-02 08:52:00-04:00,DXCM,negative
393460.0,18 Stocks Moving In Wednesday's Pre-Market Session,2016-11-02 08:43:00-04:00,DXCM,neutral
393461.0,"DexCom Reports Q3 non-GAAP Loss/Share $0.07 vs $0.13 Est, Rev $148.6M vs $146.26M Est",2016-11-01 16:24:00-04:00,DXCM,neutral
393462.0,"BTIG Research Upgrades DexCom, Inc. - Common Stock to Buy",2016-10-31 06:32:00-04:00,DXCM,neutral
393463.0,Hearing JP Morgan Defending DexCom,2016-09-28 15:37:00-04:00,DXCM,positive
393464.0,"BZ NOTE: Shares of Tandem Diabetes Care, DexCom Both Down ~7% On Medtronic's Earlier Approval Of Automated Insulin Delivery Device For Type 1 Diabetes",2016-09-28 14:13:00-04:00,DXCM,positive
393465.0,Shares of DexCom Down 7% For The Session At $87.43/Share,2016-09-28 14:06:00-04:00,DXCM,positive
393466.0,Dexcom Sells off to Low of $86.77 on Volume,2016-09-28 14:06:00-04:00,DXCM,negative
393467.0,Benzinga's Top Initiations,2016-09-27 09:34:00-04:00,DXCM,positive
393468.0,"B. Riley Initiates Coverage on DexCom at Neutral, Announces $97.00 PT",2016-09-27 04:01:00-04:00,DXCM,neutral
393469.0,Benzinga's Top Upgrades,2016-09-16 08:44:00-04:00,DXCM,positive
393470.0,Desjardins Upgrades DexCom to Buy,2016-09-16 06:36:00-04:00,DXCM,neutral
393471.0,"BTIG Moves To Neutral On DexCom, But Says Shares Are Not Overvalued",2016-09-14 10:01:00-04:00,DXCM,positive
393472.0,BTIG Research Downgrades DexCom to Neutral,2016-09-14 06:43:00-04:00,DXCM,neutral
393473.0,Reimbursement of Dexcom CGM Technology for Patients with Type 1 and Type 2 Insulin-Dependent Diabetes is Now Available in Germany,2016-09-07 16:09:00-04:00,DXCM,neutral
393474.0,"DexCom Reports Q2 GAAP EPS $(0.24) vs $(0.05) in Same Qtr. Last Year, Sales $137.3M vs $132.6M Est.",2016-08-02 17:36:00-04:00,DXCM,neutral
393475.0,BMO Capital Highlights This Week's MedTech Earnings,2016-08-01 15:14:00-04:00,DXCM,neutral
393476.0,DexCom Says FDA Advisory Committee Votes For Its Non-Adjunctive Label For G5 Mobile CGM System,2016-07-22 13:01:00-04:00,DXCM,neutral
393477.0,10 Biggest Mid-Day Gainers For Tuesday,2016-07-19 12:37:00-04:00,DXCM,neutral
393478.0,Benzinga's Volume Movers,2016-07-19 10:40:00-04:00,DXCM,neutral
393479.0,Dexcom Says FDA Published Briefing Documents Before Advisory Committee Meeting,2016-07-19 10:19:00-04:00,DXCM,neutral
393480.0,Mid-Morning Market Update: Markets Edge Lower; Goldman Sachs Profit Beats Estimates,2016-07-19 09:56:00-04:00,DXCM,positive
393481.0,Dexcom Reports FDA Posted Briefing Doc Ahead of Panel Meeting,2016-07-19 08:34:00-04:00,DXCM,neutral
393482.0,JPMorgan Bullish On Dexcom Heading Into July 21 FDA Panel,2016-06-20 14:04:00-04:00,DXCM,neutral
393483.0,Sohn Contest Winner Says Future Revenue Miss Is 'Key Catalyst' To DexCom Short Thesis,2016-05-04 16:32:00-04:00,DXCM,positive
393484.0,DexCom Shares Falling ~2% Off Sohn Idea Contest Winner's Short Thesis,2016-05-04 16:30:00-04:00,DXCM,positive
393485.0,"Sohn Idea Contest Winner On DexCom Short, Says Co. Has Insulin Pump Competition From Medtronic And Abbott",2016-05-04 16:29:00-04:00,DXCM,positive
393486.0,Sohn Idea Contest Winner Unveils Short Thesis On DexCom,2016-05-04 16:27:00-04:00,DXCM,positive
393487.0,Ira Sohn Conference 2016: The Live Blog,2016-05-04 11:52:00-04:00,DXCM,neutral
393488.0,"Dexcom Reports Purchase of Nintamed, Co.'s Distributor in Germany, Switzerland, Austria, No Terms Disclosed",2016-05-02 16:25:00-04:00,DXCM,negative
393489.0,"DexCom Reports Q1 EPS $(0.23) vs. Est. $(0.20), Rev. $116.2M vs. Est. $110.38M",2016-04-27 17:25:00-04:00,DXCM,neutral
393490.0,"BTIG Research Initiates Coverage on DexCom at Buy, Announces $80.00 PT, Says 'Valuation is Hyperglycemic, But We See More Quarterly Beats'",2016-04-14 16:26:00-04:00,DXCM,neutral
393491.0,"DexCom Reports Q4 Adj. EPS $(0.26) vs $0.01 Est., Sales $130.8M vs $123.7M Est.",2016-02-23 16:18:00-05:00,DXCM,neutral
393492.0,"Cowen Defending DXCM, Says Incorrect Reports Circulating Are Driving Selloff",2016-02-08 14:57:00-05:00,DXCM,neutral
393493.0,Benzinga's Top Downgrades,2016-02-08 09:38:00-05:00,DXCM,positive
393494.0,"Baird Downgrades DexCom to Neutral, Lowers PT to $74.00",2016-02-08 07:20:00-05:00,DXCM,negative
393495.0,"Sterne Agee CRT Defending DXCM, Says Buy on Weakness, Says Co Has Industry Leading Product And Strong Product Pipeline",2016-02-05 13:54:00-05:00,DXCM,positive
393496.0,"UPDATE: DexCom Sees Global Patient Base 140-150K as of Dec. 31, '15",2016-01-12 08:37:00-05:00,DXCM,neutral
393497.0,UPDATE: DexCom Sees FY15 Unaudited Sales of ~$400M vs $391M Est.,2016-01-12 08:36:00-05:00,DXCM,neutral
393498.0,8-K from DexCom Shows Expecting Q4 Unaudited Sales ~$129M vs $120M Est.,2016-01-12 08:36:00-05:00,DXCM,neutral
393499.0,"Dexcom Reports Q3 Adj. EPS $(0.07) vs $(0.01) Est., Sales $105.2M vs $99.9M Est.",2015-11-04 16:21:00-05:00,DXCM,neutral
393500.0,"Morgan Stanley Initiates Coverage on DexCom at Overweight, Announces $106.00 PT",2015-11-02 09:46:00-05:00,DXCM,negative
393501.0,Mid-Afternoon Market Update: Dow Jumps 175 Points; Garmin Shares Slip On Weak Preliminary Q3 Results,2015-10-15 15:28:00-04:00,DXCM,negative
393502.0,Mid-Day Market Update: Crude Oil Down 2%; Five Prime Therapeutics Shares Spike Higher,2015-10-15 12:25:00-04:00,DXCM,negative
393503.0,Mid-Morning Market Update: Markets Rise; Citigroup Profit Tops Estimates,2015-10-15 10:18:00-04:00,DXCM,positive
393504.0,Benzinga's Top Upgrades,2015-10-15 10:01:00-04:00,DXCM,positive
393505.0,Morning Market Gainers,2015-10-15 09:48:00-04:00,DXCM,neutral
393506.0,Benzinga's Top #PreMarket Gainers,2015-10-15 08:30:00-04:00,DXCM,positive
393507.0,"Leerink Swann Upgrades DexCom to Outperform, Raises PT to $100.00",2015-10-15 08:06:00-04:00,DXCM,neutral
393508.0,"Sterne Agee CRT Upgrades DexCom to Buy, Announces $90.00 PT",2015-10-15 06:04:00-04:00,DXCM,neutral
393509.0,"5 After-Hours Movers: Netflix, MBIA And More",2015-10-14 16:49:00-04:00,DXCM,neutral
393510.0,DexCom Reports Q3 Prelim Revs $105M vs Est $97.47M,2015-10-14 16:07:00-04:00,DXCM,neutral
393511.0,Dexcom Spikes to High on Volume,2015-09-10 13:08:00-04:00,DXCM,neutral
393512.0,FDA Approves Dexcom G5Â® Mobile Continuous Glucose Monitoring System,2015-08-25 08:31:00-04:00,DXCM,positive
393513.0,DexCom Reports Collaboration with The Life Sciences Team at Google Related to Breakthrough Technologies to Change Future of Diabetes Mgmt,2015-08-11 08:02:00-04:00,DXCM,neutral
393514.0,"DexCom Reports Q2 EPS $(0.05) vs. Est. $(0.03), Rev. $93.2M vs. Est. $84.81M",2015-08-05 16:13:00-04:00,DXCM,neutral
393515.0,Benzinga's Top Initiations,2015-07-08 09:51:00-04:00,DXCM,positive
393516.0,"Baird Initiates DexCom, Tandem Diabetes At Outperform On Large Growth Expectations",2015-07-08 09:47:00-04:00,DXCM,positive
393517.0,"Baird Initiates Coverage on DexCom at Outperform, Announces $95.00 PT",2015-07-08 07:13:00-04:00,DXCM,neutral
393518.0,Stocks Hitting 52-Week Highs,2015-07-01 10:29:00-04:00,DXCM,neutral
393519.0,Stocks Hitting 52-Week Highs,2015-06-29 10:31:00-04:00,DXCM,neutral
393520.0,Dexcom Reports Follow App Available/Compatible with Android Devices,2015-06-02 08:05:00-04:00,DXCM,neutral
393521.0,5 Mid-Cap Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years,2015-03-17 08:59:00-04:00,DXCM,positive
393522.0,DexCom Reports Fourth Quarter EPS of $0.02,2015-02-25 16:21:00-05:00,DXCM,neutral
393523.0,Good News For Apple Watch: FDA Steps Back From App Regulation,2015-02-09 10:51:00-05:00,DXCM,positive
393524.0,'FDA permits marketing of first system of mobile medical apps for continuous glucose monitoring',2015-01-23 16:07:00-05:00,DXCM,neutral
393525.0,From 8-K: DexCom Sees FY2014 Sales $257.0M vs $250.0M Est,2015-01-13 08:36:00-05:00,DXCM,neutral
393526.0,"Sterne Agee Downgrades DexCom to Neutral, Removes $56.00 PT",2015-01-06 06:38:00-05:00,DXCM,neutral
393527.0,"DexCom Inc Names Kevin Sayer As President, CEO; Terry Gregg Assumes Role Of Executive Chairman",2015-01-05 08:33:00-05:00,DXCM,neutral
393528.0,"Cowen & Company Initiates Coverage on DexCom, Inc. at Outperform, Announces $65.00 PT",2014-12-08 06:24:00-05:00,DXCM,neutral
393529.0,Dexcom Registers 89.3K Shares For Sale,2014-11-07 16:20:00-05:00,DXCM,positive
393530.0,"Midday Gainers From November 7: Channel Advisor, Eaton Vance, Envestnet, Interval Leisure, DexCom",2014-11-07 12:39:00-05:00,DXCM,neutral
393531.0,FDA Approves Dexcom Software With Artificial Pancreas Algorithm ,2014-11-06 08:30:00-05:00,DXCM,positive
393532.0,FDA Approves Dexcom SHARE ,2014-10-20 09:26:00-04:00,DXCM,positive
393533.0,"DexCom, Inc. Reports Q2 EPS of $(0.09) vs $(0.10) Est; Revenue of $58.80M vs $52.45M Est",2014-08-06 16:39:00-04:00,DXCM,neutral
393534.0,5 New Medical Technologies For Diabetics,2014-07-18 13:10:00-04:00,DXCM,neutral
393535.0,"8-K from Dexcom Shows Co. Entered Settlement, License Deal July 2nd with Abbott Diabetes, Party Not Acquired in Change of Control to Be Paid $25M",2014-07-07 08:33:00-04:00,DXCM,positive
393536.0,Shares of Dexcom Moving Higher Following CEO Gregg's Appearance on CNBC's Fast Money,2014-06-04 17:39:00-04:00,DXCM,positive
393537.0,DexCom CEO Gregg: 'Our Long-Term Goal is to Replace Finger Sticks',2014-05-15 18:42:00-04:00,DXCM,neutral
393538.0,DexCom CEO Gregg: 'The Individuals Who Have Diabetes Make the Choice and they Choose Us',2014-05-15 18:42:00-04:00,DXCM,neutral
393539.0,DexCom CEO Gregg: 'Our Products Allow Patients to Have Constant Monitoring of Glucose Levels',2014-05-15 18:40:00-04:00,DXCM,positive
393540.0,Jim Cramer Interviews CEO Terrance H. Gregg of DexCom on Mad Money,2014-05-15 18:37:00-04:00,DXCM,negative
393541.0,"DexCom, Inc. Reports Q1 EPS of $(0.17) vs $(0.08) Est; Revenue of $47.10M vs $44.15M Est",2014-05-01 16:20:00-04:00,DXCM,neutral
393542.0,"Sterne Agee Upgrades DexCom, Inc. to Buy, Maintains $50.00 PT",2014-04-10 08:47:00-04:00,DXCM,neutral
393543.0,"DexCom Wins FDA Warning Letter for Admin Deficiencies, Will Submit Materials to Demonstrate Compliance, Says No Sanctions Levied by FDA",2014-03-25 08:37:00-04:00,DXCM,neutral
393544.0,Mid-Morning Market Update: Markets Open Higher; Groupon Issues Weak Outlook,2014-02-21 10:34:00-05:00,DXCM,negative
393545.0,"DexCom, Inc. Reports Q4 EPS of $(0.04) vs $(0.07) Est; Revenue of $51.70M vs $48.53M Est",2014-02-20 16:24:00-05:00,DXCM,neutral
393546.0,"Feltl & Co. Downgrades DexCom, Inc. to Sell",2014-02-20 09:36:00-05:00,DXCM,neutral
393547.0,Innovative Dexcom G4Â® PLATINUM Continuous Glucose Monitor (CGM) Receives FDA Approval for Use in Children Ages 2-17 Years,2014-02-03 18:00:00-05:00,DXCM,positive
393548.0,FDA Approves Pediatric Use of Dexcom's G4 Platinum Continuous Glucose Monitoring System,2014-02-03 17:52:00-05:00,DXCM,positive
393549.0,"DexCom, Inc. Sees Q3 Sales $51.0M vs $45.80M Est",2014-01-14 08:35:00-05:00,DXCM,neutral
393550.0,"DexCom, Inc. Sees FY2014 Sales $205.0M-225.0M vs $212.70M Est",2014-01-14 08:35:00-05:00,DXCM,neutral
393551.0,Market Wrap For November 7: Markets Take A Breather As Twitter Takes Center Stage,2013-11-07 16:42:00-05:00,DXCM,neutral
393552.0,"Wedbush Maintains Outperform on DexCom, Inc., Raises PT to $39.00",2013-11-07 09:12:00-05:00,DXCM,neutral
393553.0,"Northland Securities Upgrades DexCom, Inc. to Market Perform, Raises PT to $30.00",2013-11-07 07:43:00-05:00,DXCM,positive
393554.0,"DexCom, Inc. Reports Q3 EPS of $(0.08) vs $(0.13) Est; Revenue of $42.90M vs $35.87M Est",2013-11-06 16:08:00-05:00,DXCM,neutral
393555.0,UPDATE: Benchmark Initiates Coverage on DexCom on Upside From New G4 Platinum Sensor,2013-10-15 11:30:00-04:00,DXCM,neutral
393556.0,"Benchmark Initiates Coverage on DexCom, Inc. at Buy, Announces $37.00 PT",2013-10-15 06:30:00-04:00,DXCM,neutral
393557.0,UPDATE: J.P. Morgan Initiates Coverage on DexCom on Market Leader Position,2013-09-13 11:32:00-04:00,DXCM,neutral
393558.0,Benzinga's Top Initiations,2013-09-13 07:58:00-04:00,DXCM,positive
393559.0,"JP Morgan Initiates Coverage on DexCom, Inc. at Overweight, Announces $32.00 PT",2013-09-13 07:27:00-04:00,DXCM,neutral
393560.0,"JP Morgan Initiates Coverage on DexCom, Inc. at Overweight, Announces $32.00 PT",2013-09-13 07:24:00-04:00,DXCM,neutral
393561.0,"Market Wrap for Thursday, August 8: Stocks Snap Losing Streak With Modest Rally ",2013-08-08 16:27:00-04:00,DXCM,negative
393562.0,UPDATE: Jefferies Raises PT on DexCom Following Strong 2Q Results,2013-08-08 10:42:00-04:00,DXCM,positive
393563.0,"Jefferies Maintains Buy on DexCom, Inc., Raises PT to $27.00",2013-08-08 07:43:00-04:00,DXCM,neutral
393564.0,"Wunderlich Suspends Hold Rating on DexCom, Inc., Removes $20.00 PT",2013-08-08 07:20:00-04:00,DXCM,neutral
393565.0,"DexCom, Inc. Reports Q2 EPS of $(0.14) vs $(0.16) Est; Revenue of $35.80M vs $31.13M Est",2013-08-07 16:17:00-04:00,DXCM,neutral
393566.0,"Northland Securities Downgrades DexCom, Inc. to Underperform, Raises PT to $17.00",2013-07-24 09:28:00-04:00,DXCM,positive
393567.0,UPDATE: Canaccord Genuity Raises PT on Dexcom on Multiple Catalysts Ahead,2013-06-24 10:14:00-04:00,DXCM,neutral
393568.0,"Canaccord Genuity Maintains Buy on DexCom, Inc., Raises PT to $25.00",2013-06-24 09:58:00-04:00,DXCM,neutral
393569.0,"Feltl & Co. Downgrades DexCom, Inc. to Sell",2013-06-13 09:40:00-04:00,DXCM,neutral
393570.0,UPDATE: Wunderlich Securities Downgrades DexCom to Hold on Valuation,2013-06-10 08:17:00-04:00,DXCM,positive
393571.0,"Wunderlich Downgrades DexCom, Inc. to Hold, Maintains $20.00 PT",2013-06-10 07:05:00-04:00,DXCM,neutral
393572.0,"DexCom, Inc. Reports Q1 EPS of $(0.16) vs $(0.17) Est; Revenue of $29.60M vs $28.33M Est",2013-05-01 17:00:00-04:00,DXCM,neutral
393573.0,"Wunderlich Maintains Buy on DexCom, Inc., Raises PT to $20.00",2013-03-13 06:47:00-04:00,DXCM,neutral
393574.0,"UPDATE: Oppenheimer Reiterates Perform Rating, Raises PT on DexCom on 4Q12 Revenues",2013-02-22 13:40:00-05:00,DXCM,neutral
393575.0,"DexCom, Inc. Reports Q4 EPS of $(0.12) vs $(0.16) Est; Revenue of $33.30M vs $31.09M Est",2013-02-21 16:28:00-05:00,DXCM,neutral
393576.0,"UPDATE: Wunderlich Securities Reiterates Buy Rating, Raises PT on DexCom",2013-01-14 09:17:00-05:00,DXCM,positive
393577.0,"Wunderlich Maintains Buy on DexCom, Inc., Raises PT to $18.00",2013-01-14 07:46:00-05:00,DXCM,neutral
393578.0,"Dexcom Names Kevin Sayer as COO; Sees Q4 Product Sales $31.6M, FY13 Sales $120-130M",2013-01-07 08:39:00-05:00,DXCM,neutral
393579.0,"UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on DexCom",2012-11-02 12:30:00-04:00,DXCM,negative
393580.0,"Canaccord Maintains DexCom at Buy, Lowers PT from $20 to $19",2012-11-02 08:56:00-04:00,DXCM,negative
393581.0,"Jefferies & Company Maintains DexCom at Buy, Lowers PT from $18 to $16.50",2012-11-02 07:00:00-04:00,DXCM,negative
393582.0,DexCom Reports Q3 EPS $-0.25 vs $-0.22 Est,2012-11-01 16:23:00-04:00,DXCM,neutral
393583.0,"Wedbush Securities Maintains DexCom at Outperform, Raises PT from $15 to $16",2012-10-09 08:20:00-04:00,DXCM,positive
393584.0,"Feltl and Company Maintains DexCom at Hold, Raises PT from $10.75 to $14",2012-10-08 13:28:00-04:00,DXCM,neutral
393585.0,"Canaccord Maintains DexCom at Buy, Raises PT from $14 to $20",2012-10-08 12:07:00-04:00,DXCM,neutral
393586.0,U.S. FDA Approves the Dexcom G4 PLATINUM Continuous Glucose Monitor ,2012-10-08 08:01:00-04:00,DXCM,positive
393587.0,"Option Alert: Dexcom October 15 Call; Block Trade: 2,500 Contracts @$0.65",2012-09-21 10:43:00-04:00,DXCM,negative
393588.0,"Piper Jaffray Maintains DexCom at Overweight, Raises PT from $14 to $17",2012-09-20 06:42:00-04:00,DXCM,negative
393589.0,"Jefferies & Company Maintains DexCom at Buy, Raises PT from $15 to $18",2012-09-20 06:21:00-04:00,DXCM,neutral
393590.0,"Jefferies & Company Maintains DexCom at Buy, Raises PT from $14 to $15",2012-08-07 08:31:00-04:00,DXCM,neutral
393591.0,DexCom Reports Q2 EPS $-0.21 vs $-0.20 Est; Revenues $23.5M vs $22.24M Est,2012-08-06 17:17:00-04:00,DXCM,neutral
393592.0,McNicoll Lewis Vlak Suspends Coverage on DexCom,2012-07-16 07:01:00-04:00,DXCM,neutral
393593.0,Dexcom Receives CE Mark Approval for the Dexcom G4 Continuous Glucose Monitoring System   ,2012-06-14 08:30:00-04:00,DXCM,positive
393594.0,"McNicoll Lewis Vlak Maintains DexCom at Hold, Raises PT from $9 to $10",2012-05-03 08:56:00-04:00,DXCM,neutral
393595.0,"Feltl and Company Maintains DexCom at Hold, Raises PT from $9 to $Sat Dec 30 1899 08:15:00 GMT-0800 (PST)",2012-05-03 08:35:00-04:00,DXCM,neutral
393596.0,DexCom Reports Q1 EPS $-0.21 vs $-0.19 Est; Revenues $20.1M vs $19.88M Est,2012-05-02 17:00:00-04:00,DXCM,neutral
393597.0,UPDATE: Brean Murray Carret Raises Target on DexCom to $13.50,2012-02-24 16:09:00-05:00,DXCM,neutral
393598.0,UPDATE: Canaccord Genuity Raises Target on DexCom to $11.50,2012-02-24 12:19:00-05:00,DXCM,neutral
393599.0,UPDATE: Wunderlich Securities Raises Price Target on DexCom to $15,2012-02-24 09:46:00-05:00,DXCM,positive
393600.0,"Brean Murray Carret & Co. Maintains DexCom at Buy, Raises PT from $12.5 to $13.5",2012-02-24 07:06:00-05:00,DXCM,neutral
393601.0,"Wunderlich Securities Maintains DexCom at Buy, Raises PT from $12 to $15",2012-02-24 06:05:00-05:00,DXCM,positive
393602.0,DexCom Reports Q4 EPS $(0.18) vs $(0.17) Est; Revenues $22.40M vs $21.63M Est	 				,2012-02-23 16:13:00-05:00,DXCM,neutral
393603.0,DexCom Announces Acquisition of SweetSpot Diabetes Care for $4.5M  ,2012-02-23 16:04:00-05:00,DXCM,positive
393604.0,"UPDATE: Brean Murray Carret Initiates Buy, $12.50 Target on DexCom",2012-01-17 10:56:00-05:00,DXCM,neutral
393605.0,Brean Murray Initiates DexCom at Buy,2012-01-17 07:22:00-05:00,DXCM,neutral
393606.0,Piper Jaffray Reiterates Overweight Rating on DexCom,2012-01-11 09:06:00-05:00,DXCM,negative
393607.0,Feltl and Company Lowers PT on DexCom to $9,2012-01-11 08:47:00-05:00,DXCM,negative
393608.0,Oppenheimer Reiterates Perform on DexCom,2012-01-11 08:12:00-05:00,DXCM,neutral
393609.0,Afternoon Movers; Positive US News,2011-12-29 16:07:00-05:00,DXCM,positive
393610.0,UPDATE: Wunderlich Initiates Coverage on DexCom at Buy,2011-12-29 07:41:00-05:00,DXCM,neutral
393611.0,"Wunderlich Securities Initiates DexCom at Buy, $12 PT",2011-12-29 07:04:00-05:00,DXCM,positive
393612.0,"MLV & Co. Starts Coverage Of DexCom With Buy, $11 PT",2011-12-20 11:11:00-05:00,DXCM,neutral
393613.0,McNicoll Lewis & Vlak Initiates DexCom at Buy,2011-12-20 08:38:00-05:00,DXCM,neutral
393614.0,DexCom Hits 52-Week Low of $6.75,2011-11-23 09:30:00-05:00,DXCM,negative
393615.0,DexCom Hits 52-Week Low of $6.86,2011-11-22 11:41:00-05:00,DXCM,negative
393616.0,DexCom Hits 52-Week Low of $6.89,2011-11-21 10:06:00-05:00,DXCM,negative
393617.0,Top Narrow Based Indexes For September 20,2011-09-20 10:21:00-04:00,DXCM,positive
393618.0,Morgan Keegan Maintains Outperform on DexCom,2011-09-20 09:21:00-04:00,DXCM,neutral
393619.0,Pre-Market Losers; Cincinnati Bell Down 13%,2011-08-19 09:23:00-04:00,DXCM,negative
393620.0,UPDATE: Feltl & Co Upgrades DexCom from Hold to Buy and Lowers PT from $15.85 to $15.35,2011-08-16 09:44:00-04:00,DXCM,negative
393621.0,"Feltl Upgrades DexCom To Buy, PT Raised To $15.85",2011-08-16 08:53:00-04:00,DXCM,neutral
393622.0,Hearing Negative Twitter Chatter on DexCom,2011-07-19 09:49:00-04:00,DXCM,negative
393623.0,Wedbush Reiterates Outperform and PT of $18 on DexCom,2011-06-30 08:31:00-04:00,DXCM,neutral
393624.0,Piper Jaffray Reiterates Overweight and PT of $20 on DexCom,2011-06-27 06:18:00-04:00,DXCM,negative
393625.0,Piper Jaffray Highlights DXCM's Early Continuous Glucose Management Data,2011-05-26 08:17:00-04:00,DXCM,neutral
393626.0,"Jefferies Reiterates Buy On DexCom, Raises PT To $19.50 (DXCM)",2011-05-04 13:00:00-04:00,DXCM,neutral
393627.0,UPDATE: Jefferies Raises Price Target On DexCom Following Earnings (DXCM),2011-05-04 09:05:00-04:00,DXCM,neutral
393628.0,Wedbush Raises PT On DexCom To $18 After In-Line 1Q Results,2011-05-04 09:05:00-04:00,DXCM,neutral
393629.0,DexCom Announces Board Additions; Names Kevin Sayer President (DXCM),2011-05-03 16:02:00-04:00,DXCM,neutral
393630.0,Jefferies Initiating Coverage On DexCom At Buy,2011-03-29 07:52:00-04:00,DXCM,neutral
393631.0,"Jefferies Initiates DexCom At Buy, $17 PT",2011-03-29 07:10:00-04:00,DXCM,neutral
393632.0,Piper Jaffray Reiterating Overweight On DexCom (DXCM),2011-03-04 07:49:00-05:00,DXCM,negative
393633.0,DexCom Inc. Reports Fourth Quarter and Full Year 2010 Financial Results ,2011-03-03 16:07:00-05:00,DXCM,neutral
393634.0,Takeover Candidates In Medical Tech ,2010-12-20 14:31:00-05:00,DXCM,neutral
393635.0,"Benzinga's Volume Movers (ATLS, DXCM, APEI, BSFT)",2010-11-09 10:56:00-05:00,DXCM,neutral
393636.0,DexCom EPS Meets but Sales Misses - Analyst Blog,2010-11-08 17:33:00-05:00,DXCM,negative
393637.0,DexCom Announces the Sale of 2.85 Million Shares ,2010-11-08 16:27:00-05:00,DXCM,positive
393638.0,DexCom Falls Out of Bed (DXCM),2010-11-05 12:18:00-04:00,DXCM,neutral
393639.0,DexCom Plummets 21% On Earnings And Revenue Miss(DXCM),2010-11-05 11:28:00-04:00,DXCM,neutral
393640.0,DexCom Shares Plummet 20% After Hours (DXCM),2010-11-04 19:03:00-04:00,DXCM,positive
393641.0,DexCom Inc. Reports Third Quarter 2010 Financial Results: Loss Per Share of $0.23,2010-11-04 17:00:00-04:00,DXCM,neutral
393642.0,DXCM Expects To Reach Profitability On Existing And Milestone Cash,2010-08-13 13:21:00-04:00,DXCM,positive
393643.0,"DexCom Meets, Beats on Sales - Analyst Blog",2010-08-04 12:48:00-04:00,DXCM,neutral
393644.0,William Blair Reiterates Outperform on DexCom (DXCM),2010-08-04 09:52:00-04:00,DXCM,neutral
393645.0,"Mad Money Lightning Round OT (BRCM, MGA, JCI, DXCM, ABT)",2010-07-20 20:07:00-04:00,DXCM,negative
393646.0,Piper Jaffray Reiterates Buy Rating On DexCom Despite FDA Warnings (DXCM),2010-06-02 11:48:00-04:00,DXCM,positive
393647.0,"Stocks That Created New 52-Week Highs (DXCM, EDUC, RDEN, HOMB, HBANP)",2010-01-15 14:18:00-05:00,DXCM,positive
393648.0,"Benzingaâs Top Upgrades (CMA, OMX, SPLS, DXCM, INTC, DRQ)",2010-01-15 09:14:00-05:00,DXCM,positive
393649.0,"Stocks That Created New 52 Week Highs (TDSC, ARMH, ARUN, BBBY, DXCM)",2010-01-07 13:26:00-05:00,DXCM,positive
